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Lipoprotein synthesis is controlled by estrogens, but
the exact mechanisms underpinning this regulation
and the role of the hepatic estrogen receptor a
(ERa) in cholesterol physiology are unclear. Utilizing
a mouse model involving selective ablation of ERa
in the liver, we demonstrate that hepatic ERa couples
lipid metabolism to the reproductive cycle. We show
that this receptor regulates the synthesis of choles-
terol transport proteins, enzymes for lipoprotein re-
modeling, and receptors for cholesterol uptake.
Additionally, ERa is indispensable during proestrus
for the generation of high-density lipoproteins effi-
cient in eliciting cholesterol efflux from macro-
phages. We propose that a specific interaction with
liver X receptor a (LXRa) mediates the broad effects
of ERa on the hepatic lipid metabolism.INTRODUCTION
The liver plays a unique, central role in the regulation of fatty acid
(FA) and cholesterol (CH) metabolism. Alterations in the homeo-
static control of lipidmetabolism have severe pathological reper-
cussions, as the accumulation of fat in the hepatocytes is asso-
ciated with non-alcoholic fatty liver disease (NAFLD), metabolic
disease, and cardiovascular disease (CVD).
An emerging theme in the regulation of hepatic lipid meta-
bolism is the involvement of estrogens and associated recep-
tors. Prior work has demonstrated that the liver is a major target
for estrogens, and the transcriptional activity of hepatic estrogen
receptors (ERs) is strictly associated with the reproductive cycle
(Ciana et al., 2003) and nutritional status (Ciana et al., 2005; Della
Torre et al., 2011). Several lines of evidence indicate that estro-360 Cell Reports 15, 360–371, April 12, 2016 ª2016 The Authors
This is an open access article under the CC BY license (http://creativegens are involved in the prevention of hepatic fat deposits: (1) es-
trogens reduce hepatic lipid synthesis and increase the transport
of triglycerides (TGs); (2) sex and the reproductive state influence
the prevalence of NAFLD and the degree of fibrosis in patients
with its more severe form, non-alcoholic steatohepatitis
(NASH); and (3) pathologies characterized by ovarian dysfunc-
tion, such as polycystic ovary syndrome and Turner syndrome,
are generally associated with NAFLD (Clegg, 2012; Gambarin-
Gelwan et al., 2007; Gutierrez-Grobe et al., 2010; Ostberg
et al., 2005).
Although a number of studies in experimental animals and in
women have addressed the beneficial role of estrogen signaling
in counteracting fatty liver disease/NAFLD and CVD (Barsalani
et al., 2010; Della Torre et al., 2014; Roeters van Lennep et al.,
2002), the exact mechanisms underpinning the increased inci-
dence of NAFLD following menopause and ovariectomy (OVX)
and their relation with the etiology of CVD remain unclear. Un-
derstanding the physiology of estrogen-dependent regulation
of energy metabolism in the female liver is necessary for the
development of new therapies, particularly for the treatment of
metabolic disorders associated with menopause and ovarian
dysfunction.
The model systems applied so far, i.e., OVX and total body ER
knockout (KO), have not been able to distinguish between sys-
temic and intra-hepatic estrogen effects. To overcome this
issue, we generated a conditional liver KO of ER a (ERa) (Esr1),
the predominant ER isoform in liver (LERKO). LERKOmice main-
tain a regular reproductive cycle (Della Torre et al., 2011) and,
therefore, provide a unique opportunity to study the conse-
quences of the lack of liver ERa in the context of female repro-
ductive physiology.
The aim of the present study was to investigate the physio-
logical role of hepatic ERa in the control of lipid metabolism
in females and to examine the extent to which liver ERa can
be considered a target for hepatic metabolic dysfunction
therapy.commons.org/licenses/by/4.0/).
Figure 1. Liver Histology and Measure-
ment of Esr1 Expression in the SYN and
LERKO Mice
(A) Liver histology. Top: H&E staining; the black
arrows highlight hepatocellular vacuolar degen-
eration. Center: oil red O staining plus H&E (neutral
fats are stained orange red, and the nuclei are
shown in blue). Bottom: Masson’s trichrome
staining with aberrant collagen deposits (blue); the
hepatocyte cytoplasm is red, and the nuclei are
dark red-black structures within cells. For both
SYN and LERKO: scale bar for left columns,
33 mm; scale bar for right columns, 10.6 mm.
(B) Quantitative analysis of Esr1mRNA in the livers
of 3-month-old cycling females measured by real-
time PCR; OVX for 30 days and age-matched
males. The data indicate mean ± SEM; n = 6O 12;
the experiment was repeated three times.
(C) Representative western blot and semi-
quantitative analysis of ERa protein in liver ex-
tracts. The data indicate mean ± SEM; n = 5. The
experiment was repeated three times.
*p < 0.05, **p < 0.01, and ***p < 0.001 versus SYN
at P; ##p < 0.01 and ###p < 0.001 versus SYN.RESULTS
The Selective Ablation of Esr1 Leads to an Aberrant
Deposition of Fat and Collagen in the Female Mouse
Liver
The effects of liver Esr1 ablation were initially studied in fertile
females euthanized at 10 months of age. The livers of syngenic
(SYN) and LERKO mice were dissected for morphological ex-
amination based on a combination of staining procedures (Fig-
ure 1A; Table S1). H&E staining revealed a variable degree
(from mild to marked) of hepatocellular vacuolar degeneration.
Although overt effects of Esr1 ablation were not immediately
evident, in the LERKO mice, the vacuolization was slightly
more marked, which was suggestive of changes in fat deposits.
Such changes were further suggested by the observation that,
overall, the oil-red-O-stained lipid droplets were larger in the
LERKO than in the SYN mice and that Masson’s trichrome
staining of the LERKO livers revealed portal infiltration of mono-
nuclear leukocytes and portal or centrilobular collagen deposi-
tion. Quantitative analyses demonstrated that the livers of the
LERKO mice exhibited increased oil red O staining (+112%;
Figure S1; Table S1) and a greater expression of genes
involved in the inflammatory process and collagen deposition
(Figure S2).CeInterestingly, when the study was car-
ried out in 10-month-old SYN males, we
observed that the lipid accumulation
was 4.4-fold higher than in females of
the same age; however, the effect of
Esr1 ablation in males (+28%) was less
pronounced than in females (+112%; Fig-
ure S1), thus suggesting a sexually dimor-
phic role of hepatic ERa in the control of
liver lipid homeostasis. Further investiga-tions revealed that, in males, the content of ERa protein (Fig-
ure 1C)was, indeed, significantly lower than in females. However,
the most remarkable observation was that the concentrations of
ERa mRNA and protein in females changed significantly across
the different phases of the estrous cycle; ERamRNA and protein
content was the lowest at proestrus (P) (26% and 39%,
respectively, versus metestrus [M]) and OVX further decreased
ERa protein (52% versus M).
These results might explain the minor effect of liver ERa abla-
tion in males and led us to further investigate the role of liver ERa
in lipidmetabolism in females in relation to the different phases of
the reproductive cycle.
Lipid and Lipoprotein Metabolism in the Liver: Effects of
the Reproductive Cycle and Esr1 Ablation
The following series of findings in female mouse liver indicated a
tight coupling between the reproductive cycle and CH meta-
bolism (Figure 2): total CH content oscillated with the estrous cy-
cle, and free/total CH was the lowest during diestrus (D); in this
phase of the cycle, the ratio between cholesteryl esters (CEs)
and total CH was the highest. CH catabolism was also regulated
as indicated by measurements of bile acid (BA) contents in the
feces, which were lower at estrus (E) and M than at P and D.
These changes were not observed in the LERKO mice, whichll Reports 15, 360–371, April 12, 2016 361
Figure 2. Effect of Estrous Cycle Progres-
sion on Liver CH Metabolism in the SYN
and LERKO Female Mice
Liver extracts were obtained from the livers of
3-month-old female mice.
(A–C) Total CH content (A). Free CH (B) and CE (C)
content expressed as a percentage of the total
CH. The data indicate mean ± SEM; n = 10.
(D) BA content measured in the feces. The data
indicate mean ± SEM; n = 10.
(E and F) TG (E) and FFA (F) liver contents. The
data indicate mean ± SEM; n = 5.
(G) Representative western blotting analyses of
the contents of apo-AI, apo-E, SR-B1, and LDLR
in liver extracts.
(H) Semiquantitative analyses of blotting with an-
tibodies anti-apo-AI, -apo-E, -SR-B1, and -LDLR.
The data indicate mean ± SEM of six animals. The
experiment was repeated twice.
*p < 0.05, **p < 0.01, and ***p < 0.001 versus SYN
at P; OOp < 0.01 versus LERKO at P; #p < 0.05,
##p < 0.01, and ###p < 0.001 versus SYN.led to the conclusion that, in the absence of liver ERa, hepatic CH
metabolism and ovarian activity are uncoupled (Figures 2A–2D).
In contrast, measurements of hepatic TG content and free
fatty acids (FFAs) revealed no influence of the estrous cycle in
the SYN mice, whereas in the LERKO livers, TGs accumulated
during M and FFA decreased during E, which highlighted a role362 Cell Reports 15, 360–371, April 12, 2016of ERa in the maintenance of TGs and
FFA homeostasis in the liver (Figures 2E
and 2F).
Next, we studied the proteins involved
in CH transport: in SYN mice, both syn-
thesis and uptake of high-density lipo-
proteins (HDLs) appeared to be the
lowest at M, as indicated by the content
of apolipoprotein-AI (apo-AI) and apoli-
poprotein-E (apo-E) and their receptor
(scavenger receptor class B member;
SR-B1). A different pattern was observed
for the low-density lipoprotein (LDL) re-
ceptor (LDLR), the hepatic content of
which was the highest at E. Again, none
of these cycle-related changes were
observed in the LERKO mice (Figures
2G and 2H).
To verify whether the differences
observed in the estrous cycle of SYN
and LERKO females were not caused
by increased levels or altered fluctuation
of 17b-estradiol (E2) in the plasma of
LERKO, we measured the circulating
levels of the hormone in each phase of
the cycle by gas chromatography-tan-
dem mass spectrometry (GC-MS/MS),
and we analyzed uterus weight as a
well-known quantitative bioassay for
circulating estrogens. Figure S3A showsthat the circulating levels of E2 fluctuate similarly in SYN and
LERKO; the same is true for the weight of the uterus (Fig-
ure S3B). This was expected, as we did not observe any
fertility phenotype in LERKO and demonstrated that the
absence of liver ERa was the major cause of the changes prior
described.
Figure 3. CH Profiles and Lipoprotein Ana-
lyses of the Plasma of the SYN and LERKO
Females
Plasma was obtained from SYN and LERKO fe-
males at 3 months of age euthanized at different
phases of the estrous cycle or 30 days after OVX.
(A) Representative profile of the total CH content
(expressed as milligrams per deciliters) in the
fractions of plasma separated by FPLC. The
experiment was repeated three times with six
different animals in each experimental group.
(B and C)Western blot for apo-AI (B) and apo-E (C)
in the FPLC fractions of the plasma at P and E.
(D) Sizes of HDLs (d = 1.063–1.21 g/ml) purified by
sequential ultracentrifugation from pooled plasma
samples. The data indicate mean ± SEM; n = 3
pools of plasma (each pool was composed of the
plasma of six mice).
(E) Real-time PCR quantitative analyses of the liver
mRNA contents of Pltp (top) and Lipc (bottom).
The data indicate mean ± SEM; n = 6. The
experiment was repeated twice.
(F) CEC as measured by radioisotopic assay in
J774 cells pre-radiolabeled with 3H-CH and incu-
bated with plasma from either SYN or LERKO
females at P or E. The data are expressed as the
percentage of the radioactivity released into the
medium over the total radioactivity incorporated
by the cells. The data indicate mean ± SEM;
n = 10.
*p < 0.05 and ***p < 0.001 versus SYN at P; #p <
0.05, ##p < 0.01, and ###p < 0.001 versus SYN.Liver ERa and HDL Remodeling and Function
When we analyzed total plasma CH (Figure S4), we did not
observe changes associated with the estrous cycle in either
SYN or LERKO mice. Conversely, the plasma TG levels ap-
peared to be regulated by cycle-dependent factors, because os-
cillations in their levels were observed in both SYN and LERKO
mice. The TG content was slightly decreased in the SYN mice
at M (17%) and increased in the LERKO mice at D (+20%).
CH distribution among plasma lipoproteins was analyzed by
fast protein liquid chromatography (FPLC). Figure 3A shows
that, in the SYN mice, the CH-lipoprotein profile was very repro-
ducible across all phases of the estrous cycle, with the exception
of P, in which we observed a significant delay in the elution of theCeHDL peak. Indeed, in the plasma of the
SYN mice at E, M, and D, CH eluted in
fractions 31–33, whereas at P, the CH
eluted in fractions 36–38. This observa-
tion suggested that the HDLs were
smaller during P. This phenomenon was
not observed in the plasma of the LERKO
mutants, in which the FPLC profiles of the
HDLs were the same in all the phases of
the cycle and were superimposable to
those of the SYN mice at E, M, and D.
These findings provided evidence for
the involvement of liver ERa in the gener-
ation of a distinct class of HDLs during P(when the circulating estrogens were the highest) and led us to
investigate the consequences of OVX. In OVXmice, CHwas pre-
sent in the HDLs (eluting in fractions 31–33) and in the other clas-
ses of lipoproteins (very low-density lipoprotein [VLDL] and LDL),
showing a CH profile similar to that of E (the phase of the estrous
cycle with the lowest concentration of estrogens).
A further characterization of the proteins that eluted with CH
proved that the apo-AI protein content was markedly increased
in fractions 32 and 33 in all samples, with the exception of those
from the SYN mice at P, in which apo-AI was most abundant in
fractions 36–38. This finding confirmed that the late-eluting frac-
tions contained small HDL particles. Similar results were ob-
tained when we studied the apo-E distribution; apo-E was foundll Reports 15, 360–371, April 12, 2016 363
Table 1. HDL Composition
HDL
Mean ± SEM for Composition (%)
SYN P SYN E LERKO P LERKO E
Proteins 50.1 ± 1.0 54.8 ± 0.8* 52.0 ± 0.8 51.7 ± 2.1
PLs 18.4 ± 0.9 19.4 ± 0.7 21.1 ± 2.2 21.1 ± 2.2
Unesterified CH 2.8 ± 0.1 2.1 ± 0.5 3.1 ± 0.6 3.0 ± 0.6
Esterified CH 23.7 ± 0.9 21.2 ± 1.4 21.1 ± 3.9 21.3 ± 1.0
Triglycerides 5.2 ± 0.9 2.5 ± 0.4* 3.0 ± 0.5 3.1 ± 0.4
HDLs (d = 1.063–1.21 g/ml) were purified by sequential ultracentrifuga-
tion from the plasma pooled from sixmice. Protein, PL, total and unesteri-
fied CH (TC and UC), and TG contents were measured as explained in
the Experimental Procedures. The data are mean ± SEM; n = 3 pools of
plasma. *p < 0.05 versus SYN at P by two-way ANOVA followed by
Bonferroni post hoc tests.in fractions 32–34 in all the plasma samples examined, with the
exception of those from P of the SYN mice, in which apo-E
appeared in fractions 34–38.
To better characterize the HDLs circulating at P in the SYN
mice (P-HDL), we studied their sizes with non-denaturing poly-
acrylamide gradient gel electrophoresis (GGE) and studied their
mass composition. SYN P-HDLs were significantly smaller than
those circulating at E and those in the LERKO mice (Figure 3D),
and theywere characterized by a high TGcontent (+108%versus
E) and a small, but significant, reduced content of proteins
(8.6% versus E). No changes were observed in the amounts
of CH (esterified or unesterified) or phospholipids (PLs; Table
1). In the LERKO mice, the compositions of plasma HDLs at P
and E were extremely similar and not significantly different from
those of the SYN mice at E (Table 1). The analysis of the PL con-
tents of the FPLC eluate gave results consistent with the findings
shown in Figure 3A; indeed, a major PL peak was observed
around fraction 38 in the SYN mice at P and around fraction 32
in all the other samples (Figure S5). Because circulating lipopro-
teins undergo significant changes in size due to the activities of
specific remodeling enzymes, we studied the effects of the cycle
and liverEsr1ablation on the expression of thegenes that encode
PL transfer protein (Pltp) and hepatic lipase (Lipc). In the SYN
mice, the liver content of both enzymes changedwith the estrous
cycle (the lowest concentrations were observed at M). Again, no
change was observed in the LERKO mice (Figure 3E).
These results provided strong evidence that the P-HDLs were
structurally dissimilar from the lipoproteins generated during the
other phases of the estrous cycle and that the activity of liver ERa
was essential for their production. Next, we considered whether
the peculiarities of the P-HDL structure reflected key aspects of
their function by comparing the capacities of HDLs isolated from
the SYN and LERKO mice to elicit CH efflux from macrophages.
The HDL CH efflux capacity (CEC) estimates the efficiency of the
entire reverse CH transport (RCT) process and is an accepted in-
dex of HDL functionality (Rohatgi et al., 2014). We used the mu-
rine macrophage cell line J774, which is known to express the
ATP binding cassette transporter A1 (ABCA1) upon induction
with a cyclic AMP (cAMP) analog (Favari et al., 2013). Figure 3F
shows that, in SYN mice, P-HDL efficiency in inducing CH efflux
was significantly greater than that of HDL isolated at E (+23%).
This cycle-dependent effect was not observed in the LERKO364 Cell Reports 15, 360–371, April 12, 2016mice; indeed, the functionality of the LERKO HDL was indistin-
guishable from that of SYN HDL at E.
Overall, these data demonstrated that, during the course of
the reproductive cycle, the ability of HDL to elicit RCT changed
in relation to plasma estrogen content and hepatic ERa activity.
These findings led us to further evaluate the extent to which liver
ERa was able to translate ovarian output into changes in liver
metabolism via a metabolomics analysis of plasma samples
collected at P and E. Figure S6A indicates that the transition
from P to E in the SYN mice was associated with changes in
5.3% of all plasma metabolites. In LERKO mice, 34% of these
metabolites were not affected by the estrous cycle, which under-
scored the role of liver ERa in the control of the hepatic endocrine
functions. Comparison of the SYN and LERKO samples indi-
cated that the plasma metabolites differed between these
groups by 4.9% during P and 2.7% during E, which suggests
that 45% of these differences were induced by ligand-depen-
dent activation of liver ERa (see Figure S6B).
Therefore, in addition to lipoproteins, several plasma compo-
nents were regulated by ERa, further suggesting the involvement
of this receptor in the functional coupling of liver to the ovarian
cycle. The breadth of ERa effects on lipid metabolism led us
to further investigate on the underpinning mechanisms.
Hepatic ERa Cross-Couples with LXRa but Not PPARa
Previously, two ligand-dependent transcription factors, peroxi-
some proliferator-activated receptor alpha (PPARa) and liver X re-
ceptoralpha (LXRa), havebeen found toact in the liver as themajor
nutritional sensors and key transcriptional modulators of lipid and
carbohydratemetabolism (Bocher et al., 2002; Li andGlass, 2004;
Zhang et al., 2012). This led us to ask whether ERa had any effect
on the synthesis or activity of these two receptors. No changes in
PPARa mRNA or protein contents were observed in the different
phasesof the reproductive cycle (Figure 4A). Similarly, no changes
in the activity of PPARawere attributable to the progression of the
estrous cycle, because the liver contents of PPARa target genes,
such as carnitine palmitoyltransferase 1A (Cpt1a), hydroxyacyl-
coenzyme A (CoA) dehydrogenase a (Hadha), acyl-CoA oxidase
1 (Acox), and acyl-CoA synthetase long-chain family member 1
(Acsl1), were the same in all phases of the cycle (Figure 4B). These
results were replicated in the LERKO mice in which the expres-
sions of PPARa and its target genes were superimposable with
the patterns observed in the SYN mice. This suggested that the
aforementioned effects reported of hepatic ERa on liver meta-
bolism did not occur via PPARa.
In contrast, LXRa expression was modulated by the estrous
cycle in the SYN mice. A significant increase of both LXRa
mRNA and protein was observed at E (+13% and +45%, respec-
tively, versus P; Figure 4C). The estrous cycle affected also LXRa
transcriptional activity, as indicated by the changes in the liver
content of the mRNA encoded by its target genes in SYN mice;
for most of the LXRa target genes investigated (four of six), the
respectivemRNAwasdecreasedatM (i.e., ATP-binding cassette
sub-family G member 5, Abcg5; ATP-binding cassette trans-
porter A1, Abca1; CH 7-alpha-hydroxylase, Cyp7a1; and sterol
27-hydroxylase, Cyp27a1). No cycle-related changes were
observed in the expression of small heterodimer partner (Shp)
and sterol regulatory element binding protein-1c (Srebp-1c),
Figure 4. Effect of the Estrous Cycle on
PPARa and LXRa Syntheses and Transcrip-
tional Activities
(A) The PPARa mRNA (top) and protein (bottom)
liver contents were measured by real-time PCR
and western blot analysis.
(B) Real-time PCR quantitative analyses of the
PPARa target genes Cpt1a, Hahda, Acox, and
Acsl1.
(C) mRNA (top) and protein (bottom) of LXRa
contents in liver homogenates from the SYN and
LERKO mice.
(D) The mRNA contents of the LXRa target genes
Abcg5, Abca1, Cyp7a1, Cyp27a1, Shp, and
Srebp-1c.
For all of the real-time PCR analyses, the data
indicate mean ± SEM, n = 6. The experiments
were repeated three times. *p < 0.05, **p < 0.01,
and ***p < 0.001 versus SYN at P; Op < 0.05, OOp <
0.01, and OOOp < 0.001 versus LERKO at P; #p <
0.05, ##p < 0.01, and ###p < 0.001 versus SYN.the LXRa target gene master regulator of de novo lipogenesis.
The results obtained in the LERKOmice underscored the neces-
sity of ERa for the cycle-dependent expression of these factors,
because the liver content of LXRa protein or Abca1, Cyp7a1, or
Shp mRNAs was not affected by the progression of the estrous
cycle. Curiously, Cyp27a1 and Abcg5 exhibited oscillations
with the cycle in LERKO too, but the pattern of these fluctuations
differed from those of the SYN mice, pointing to the involvement
of cycle-dependent factors, which became predominant only in
the absence of the hepatic ERa (Figure 4D).
Overall, these data suggested the existence of a physiological,
functional cross-coupling between ERa and LXRa in the liver for
the regulation of CH metabolism.
Hepatic ERa Interferes with the Transcriptional Activity
of LXRa but Not PPARa
The existence of a functional interaction between ERa and
LXRa was further investigated in co-transfection studies. Fig-Ceure 5A shows that the LXRa-dependent
activity of the LXRE-Luc promoter was
augmented 13.6-fold in the presence
of the LXRa-specific agonist T0901317
(T09). Co-transfection with increasing
concentrations of ERa in the presence
of 10 nM E2 substantially diminished
LXRa transcriptional efficiency (from
9.3- to 5.0-fold at the highest ERa con-
centration). However, when the ERa
antagonist ICI 182,780 was added, ERa
inhibition was maintained. This high-
lighted the possibility of a ligand-inde-
pendent effect of ERa, which was further
demonstrated in transfection experi-
ments performed in the absence of E2
(data not shown). Remarkably, this effect
was specific to LXRa, because the tran-
scriptional activity of PPARa that wasstimulated by its agonist WY-14,643 was not altered by the pres-
ence of ERa with E2 or E2 plus ICI 182,780 (Figure 5B). Next, we
asked whether the unliganded ERa was able to interfere with
LXRa activity on the ABCA1 and SREBP-1c promoters. Figures
5C and 5D show that ERa interfered with LXRa transcriptional
activity on the ABCA1, but not of the SREBP-1c promoter. This
was consistent with prior observation (Figure 4D) that the tran-
scription of SREBP-1c in liver was not modulated by the estrous
cycle or influenced by the absence of liver ERa.
ERa and LXRa Functional Interaction in Liver
Next, we investigated the hypothesis that ERa-dependent mod-
ulation of LXRa transcriptional activity was due to a competition
between ERa and LXRa for common co-regulators. The mutual
interference of ERa and LXRa in the recruitment of common
co-activators was studied using fluorescence resonance en-
ergy transfer (FRET; Figures 5E and 5F). In this assay, we
observed that the addition of increasing amounts of ERa proteinll Reports 15, 360–371, April 12, 2016 365
Figure 5. Inhibition of the Transcriptional
Activity of LXRa by ERa: In Vitro Studies
(A) HeLa cells were co-transfected with LXRa and
the reporter LXRE-Luc in the presence or absence
of ERa. Where indicated, LXRa agonist T0901317
(T09), E2 plus T09, and ERa antagonist ICI 182,780
(ICI) were added. The data indicate mean ± SEM,
n = 4; each experiment was repeated three times.
VEH, vehicle. ***p < 0.001 versus LXRa/LXRE-
Luc+T09; Op < 0.05 and OOOp < 0.001 versus
LXRa/LXRE-Luc+E2+T09;
#p < 0.05 and ###p <
0.001 versus LXRa/LXRE-Luc+ICI+E2+T09.
(B) Effect of ERa on the transcriptional activity of
PPARa. The cells were co-transfected with PPARa
and the reporter PPRE-Luc in the presence or
absence of ERa. Where indicated, the cells were
treated with the PPARa agonist WY-14,643 (WY),
E2 + WY, and ICI + E2 + WY. The data indicate
mean ± SEM, n = 4; the experiment was repeated
three times.
(C and D) HeLa cells were co-transfected with
LXRa and the reporter ABCA1-Luc (C) or
SREBP1C-Luc (D) in the presence or absence of
ERa. Treatments were done with vehicle, T09, or
E2 + T09. The data indicate mean ± SEM, n = 4;
each experiment was repeated three times. *p <
0.05, **p < 0.01, and ***p < 0.001 versus VEH; Op <
0.05 and OOOp < 0.001 versus LXRa/ABCA1-
Luc+T09; +p < 0.05 and +++p < 0.001 versus LXRa/
ABCA1-Luc+E2+T09.
(E) Identification of the co-activators of the LXRa
(top) and ERa (bottom) proteins by FRET. SRC-1,
PGC-1a, RIP140, CBP, TIF2, nuclear receptor
corepressor (NCoR), and TRAP220. The data
indicate mean ± SEM, n = 2; the experiment was
repeated twice.
(F) FRET analysis of the changes in the recruitment
of co-activators by LXRa in the presence of
increasing amounts of ERa stimulated with DMSO
(dark lanes) or 5 nM E2 (red lanes). The data indi-
cate mean ± SEM, n = 2; the experiment was
repeated three times.
BLI, bioluminescence imaging; RLU, relative light
units.progressively augmented the competition with LXRa for steroid
receptor coactivator 1 (SRC-1), nuclear receptor interacting pro-
tein (RIP140), transcriptional intermediary factor 2 (TIF2), and thy-
roid hormone receptor-associated protein (TRAP220). No effect
was seen in the recruitment of PPARg coactivator 1-alpha
(PGC-1a) and transcriptional regulator CBP (CBP) by LXRa. No
differences in co-activator recruitment were observed in the
presence of vehicle (DMSO) or E2 (5 nM), which indicates that
the competition was ERa dependent but ligand independent.
This further confirmed the antagonist activity of unliganded ERa
reported in Figures 5A and 5C. To better evaluate the physiolog-
ical significance of the two assays, we measured the relative
concentrations of ERa and LXRa in the liver by qPCR; we found
the results to be 1:13 at P and 1:15 at E, as the concentrations366 Cell Reports 15, 360–371, April 12, 2016of the two mRNAs change across the
estrous cycle. In the transfection and
FRET assays, ERa interference wasobserved with a stoichiometry of at least 1:5, indicating that in
the in vitro assays, the proportion between ERa and LXRa was
significantly different than in liver. This ledus to verify thepotential
for interaction of the two receptors on the promoter of the genes
responsive to the presence/absence of ERa. Prior studies in liver
on chromatin immunoprecipitation (ChIP) with ERa (Gao et al.,
2008) and LXRa (Boergesen et al., 2012) supported the idea of
a cross-coupling between the two hepatic receptors, showing
that they recognized overlapping sites (see Figure S7) in the pro-
moter/enhancer of several genes of lipid metabolism. Therefore,
wecarriedout a seriesofChIP-qPCRstudies on female livers har-
vested at each phase of the estrous cycle. Figure 6 shows that
ERa and LXRa recognize and bind the same regions of chromatin
and that the reproductive cycle has a significant influence on the
Figure 6. ERa and LXRa Functional Interaction in Liver
(A) Recruitment of ERa (upper) and LXRa (lower) by conventional ChIP followed by qPCR. ChIP was done using ERa antibody, LXRa antibody, or normal rabbit
IgG as negative control. After reverse cross-link, the purified ChIP-enriched fragments were amplified using qPCR, with primers that target the selected regions
(see Supplemental Experimental Procedures). For each gene, the recruitment of ERa or LXRa is expressed as ratio of the fold enrichment relative to occupancy in
IgG-precipitated samples versus the FE of the negative control FoxL2: an exonic region not bound by any nuclear receptor in this cell type.
(B) ERa-LXRa cross-coupling over the course of the mouse reproductive cycle. In P, the high concentration of circulating estrogens enhances ERa binding to
DNA, thereby promoting LXRa binding and transcriptional activity. In M, circulating estrogens are low, ERa binding to DNA is loosened, and LXRa binding to DNA
and transcriptional activity are reduced.
The data indicate mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 versus SYN at P.extent to which both receptors interact with the promoter/
enhancer of several of the genes relevant for CH metabolism.
Most important is the finding that, in general, ERamaximal bind-
ing to the promoter/enhancer of the genes studied occurs at P,
when estrogen production is highest; the observation that the
target DNA co-precipitatedwith ERa at E shows that the receptor
associationwith these promoters persists in time. Formost of the
promoters/enhancers studied, LXRa binding was generally
higher at P, thus indicating the potential for a positive co-opera-
tion between the two hormonally regulated transcription factors.
These observations led us to propose that, at the end of the follic-
ular phase, during P, the high levels of estrogens promote the
binding of ERa to the DNA in regions proximal to LXR-binding
sites facilitating the transcription of LXRa target genes. Thedecreased concentration of estrogens loosens ERa interactions
with both the DNA and LXRa: the consequence is the decreased
synthesis of mRNA observed at M (Figure 6D). Consistent with
the expression studies, the association of ERa with the Srebp1-
1c promoter did not change significantly with the cycle; quite un-
expected, however, was the finding that the highest fluctuation of
LXRa binding across the cycle was observed on the Srebp-1c
promoter, in spite of the fact that the amount of Srebp-1c
mRNA is not influenced by the cycle.
DISCUSSION
The present study demonstrates that ERa is essential for coupling
liver CH metabolism to ovarian cycle and for the recurrentCell Reports 15, 360–371, April 12, 2016 367
production of a class of HDLs uniquely suited for CH efflux; in
addition, the study suggests the existence of a functional interac-
tion between LXRa and ERa possibly designed to better adapt
hepatic lipid metabolism to the needs of reproductive functions.
Liver ERa and HDL Structure and Function
Hepatocytes are the major site of CH metabolism and transport.
Lipoproteins synthesized by the liver transport CH to peripheral
tissues and retrieve CH from non-hepatic tissues when CH con-
centration is excessive through a process called ‘‘reverse CH
transport’’ (RCT). RCT is a potent defense mechanism against
CH accumulation that is performed by HDLs. The efficiency of
CH efflux from peripheral cells is determined by the size, shape,
and composition of the HDLs (Gursky et al., 2013). HDL protein
and lipid composition is also dependent on the activity of several
remodeling enzymes (Rye and Barter, 2014). These enzymes
include PL transfer protein (PLTP), which mediates PL transport
among HDLs and reduces the number of small HDL particles, li-
pases (hepatic andendothelial) that hydrolyzeTG-enrichedHDLs
to generate small HDL particles, and CE transfer protein (CETP).
Here, we show that, in fertile females, HDLs periodically un-
dergo a significant structural and functional remodeling that is
liver ERa dependent and results in HDL reduction in size and
increased ability to promote CH efflux. This effect might be
caused by ERa-dependent regulation of the genes encoding (i)
HDL remodeling enzymes or (ii) specific apolipoproteins more
efficient in CH transport.
Indeed, we found that liver ERawas required for the differential
expression of the genes encoding PLTP and hepatic lipase
observed across the estrous cycle. This finding is consistent
with the results of previous studies that have demonstrated
that these enzymes are subject to hormonal regulation in exper-
imental models and humans. The mechanism underlying this
regulation remains to be better studied, because ERa was
shown to repress or induce the transcription of the lipase gene
depending on the nature, concentration, and mode of adminis-
tration of the estrogenic compounds (Brinton, 1996; Tilly-Kiesi
et al., 1997). The discrepancies in the literature suggest that
the activity of ERa on the promoters of these genes does not
occur via the direct binding to the estrogen responsive element
(ERE) but rather involves the regulation of other transcription fac-
tors, such as c-fos, that modulate these genes via AP-1 binding
sites (Jones et al., 2002).
On the other hand, the finding that P-HDLs carry a quantity of
TGs twice that of the HDL isolated at E, in spite of their low di-
mensions and protein content (Table 1), supports the view that
the P-HDLs are made of specific proteins able to bind lipids
with high affinity and to reduce the size of these particles.
A good candidate could be apolipoprotein M (apo-M), shown
to be regulated by estrogen-activated ERa (Wei et al., 2011)
and by LXRa (Nielsen et al., 2009) in several models. ApoM is pri-
marily present in HDL, and the absence of its synthesis was
associated with unusually large HDLs and the disappearance
of pre-b-HDLs (highly relevant for CH efflux from macrophages).
Liver ERa and CH Transport and Uptake
This study showed that hepatic ERa is necessary for circulating
estrogens to regulate a panoply of mechanisms that aim to368 Cell Reports 15, 360–371, April 12, 2016achieve a more dynamic HDL reshaping and more efficient
RCT. During P in mice expressing liver ERa, HDL synthesis
(apo-E and apo-AI, and possibly others) and uptake (SR-B1
and LDLR) were increased, the transcriptions of genes that
encode remodeling enzymes (Pltp and Lipc) changed, and he-
patic CH transport (Abca1 and Abcg5) was high; these observa-
tions indicate a role of the receptor in the coordination of these
functions that is relevant to CH use and disposal.
We also observed the effects of the cycle on VLDLs and
LDLs, which represent minor components of the circulating li-
poproteins in mice. The CH profiles (Figure 3A) of mice with
low-circulating estrogens (i.e., the mice at E and M and the
OVX mice) exhibited peaks of higher molecular weights that
are known to correspond to VLDL and LDL; these peaks disap-
peared or changed size with increases in circulating estrogens
(i.e., during D and P). However, these changes were also
observed in the LERKO mice, suggesting that liver ERa is not
the only factor that regulates the metabolism of plasma LDL
and VLDL in mice.
This strong dependence of liver ERa on the ovarian production
of estrogens might easily explain why CH and lipoprotein meta-
bolism are heavily affected by estrogen loss in OVX animals and
why women, who appear to be protected against fatty liver dis-
ease/NAFLD and CVD during fertile ages, exhibit an increased
incidence of these pathologies early after menopause.
Functional Interaction between LXRa and ERa
The present study shows that, in the liver, ERa is necessary to
regulate LXRa activity on a selected subset of its target genes.
ChIP-qPCR analyses suggest that ERa control on LXRa tran-
scriptional activity occurs via an interaction of the two receptors
on the promoter/enhancer region of LXRa target genes. The
concomitant presence of ERa and LXRa occurs mainly at P,
the phase of the estrous cycle where we measured the highest
expression of LXRa target genes: this indicates that (1) ERa is
hormone activated when co-recruited to the DNA and (2) ERa
promotes LXRa transcriptional activity. This appears to be in
contradiction with the transfection and FRET studies, in which
we found that the unliganded ERa represses LXRa transcrip-
tional activity or binding to co-regulators; the reason for this
difference is likely ascribable to the vast excess of the ERa
necessary to measure ERa effects in the in vitro studies. Thus,
the in vitro studies might suggest the possibility of a variety of
functional interactions between the two receptors, which can
be achieved by changing receptor and ligand concentrations.
This flexibility may be very relevant from the physiological point
of view required to provide the degree of variability indispens-
able for adapting liver lipid metabolism to the needs of the
reproductive systems throughout development, pregnancy,
and lactation.
Prior work showed that ERa transcriptional efficiency is very
sensitive to hormonal dosages, and, depending on its concen-
tration, the same ligand can induce opposite effects (Calabrese,
2001; Li et al., 2007); this study suggests that receptor dosage is
also functionally relevant and needs to be taken into consider-
ation when analyzing ERa activities. These findings reveal how
critical the interpretation is of experiments conducted with the
OVX/hormone replacement paradigm, in which the ERa cell
content may be significantly changed and natural or powerful
synthetic ligands are used at high doses. Indeed, using this latter
paradigm, Han et al. reached conclusions opposite to ours, by
showing that liver ERa represses lipid synthesis through a func-
tional interaction with LXRa on the SREBP-1c promoter (Han
et al., 2014).
Conclusions
We propose that the sequence of the events that is regulated by
liver ERa across the different phases of the estrous cycle is
necessary for the clearance of the excess of CH that the liver pro-
duces and transports to the periphery during specific phases of
the reproductive cycle. Possibly, this mechanism was selected
during evolution to ensure that the excess of CH made available
under the pressure of the reproductive system was not wasted
but could be efficiently re-utilized.
At the present time, in which dietary CH is excessive, the
mechanism mentioned earlier has become important for health
because the periodic production of highly efficient HDL might
protect fertile women against the formation of undesired de-
posits of lipids in the peripheral tissues or blood vessels. At the
same time, the tight cross-coupling between liver ERa and
LXRa efficiently regulates hepatic lipid homeostasis to meet
the requirements of the different reproductive stages. With the
cessation of ovarian activity, this finely tuned sequence of events
is disrupted, enabling the initial formation of unhealthy deposits
of lipids in both the liver and periphery. Indeed, it is known that
the dysregulation of CH metabolism is associated with the
severity of fatty liver disease/NAFLD (Bashiri et al., 2013; Min
et al., 2012) and that menopause increases the prevalence of
fatty liver disease/NAFLD (Gutierrez-Grobe et al., 2010), as well
as a number of associated pathologies.
Notwithstanding the differences in CH homeostasis in mice
and humans (Xiangdong et al., 2011), these findings might also
explain the sexually dimorphic prevalence of hepatic and cardio-
vascular disorders among humans under 50 years of age. Males
express minimal amounts of ERa in the liver and, unlike women,
do not synthesize super-efficient HDL at regular intervals. There-
fore, even minimal derangements in lipid homeostasis might
cause undesired accumulations of lipids over time that increase
men’s susceptibilities to pathologies associated with altered
lipid metabolism.
Finally, the identification of liver ERa as an important factor for
hepatic metabolic homeostasis underscores its importance as a
primary target for post-menopausal hormone replacement ther-
apy (HRT), because the appropriate maintenance of liver ERa
activity after menopause might be the key for the prevention of
disorders associated with unbalanced CH metabolism. The cy-
clic activation of liver ERa would reduce cardiovascular risks
by promoting CH efflux from macrophages and BA synthesis
without increasing fatty acid synthesis and their plasmatic levels.
The use of a estrogenic compound would, therefore, be prefer-
able over LXR agonists which have the main undesired effect
of increased FA content in the liver and in the plasma (Joseph
et al., 2002). Therefore, we propose the development of an
appropriate HRT that targets liver ERa as a therapy of choice
for the prevention of liver and cardiovascular disorders associ-
ated with the post-menopausal period.EXPERIMENTAL PROCEDURES
Animals
The LERKOmice were obtained andmaintained as previously described (Della
Torre et al., 2011). Unless otherwise stated, the mice were 3 months of age.
Vaginal smears were performed at 9:00 a.m. To avoid any possible confound-
ing effect due to the circadian rhythm or feeding status, the mice were eutha-
nized after 6 hr of fasting between 2:00 and 4:00 p.m. (Della Torre et al., 2011).
All animal experimentation was performed in accordance with the ARRIVE
guidelines and the European guidelines for animal care and the use of exper-
imental animals, approved by the Italian Ministry of Research and University,
and controlled by a departmental panel of experts.
Liver Histology
See Supplemental Experimental Procedures.
FPLC Analyses
The CH distribution in the plasma lipoprotein fractions was determined via
FPLC using a Superose 6 column (Amersham Biosciences). 500-ml fractions
were collected and assayed for CH with an enzymatic kit (Sentinel).
HDL Purification, Composition, and Size
HDLs (d = 1.063–1.21 g/ml) were purified from pooled plasma samples by
sequential ultracentrifugation, using a TL100.3 rotor in a TL100 ultracentrifuge
(Beckman Coulter). The total and unesterified CH (TC and UC, respectively),
TG, and PL contents of the isolated lipoproteins were measured by standard
enzymatic techniques. The CE mass was calculated as (TC  UC) 3 1.68.
The protein content was assessed by the Lowry method. The HDL composi-
tion was calculated as the percentage of the particle total mass. HDL particle
sizes were analyzed by non-denaturing polyacrylamide GGE using precast
4%–30% acrylamide gels (CBS Scientific). Coomassie-stained gels were
scanned with a GS-690 densitometer, and particle sizes were calculated
with the Multi-Analyst software (Bio-Rad).
CEC
See Supplemental Experimental Procedures.
Biochemical Assays
The CH, CE, FFA, and Tg levels in the liver tissues were measured with appro-
priate kits according to the manufacturer’s protocols (Biovision).
Fecal BA Excretion
Dried feces were extracted in 1ml of 75% ethanol at 50C for 2 hr. The extracts
were centrifuged, and the supernatants were diluted 20-fold with 65mMphos-
phate buffer at pH 7.0. BA concentration was measured with an enzymatic kit
(Sentinel).
Western Blot Analysis
See Supplemental Experimental Procedures.
Real-Time PCR Gene Expression Analysis
Total liver RNA extraction, cDNA synthesis, real-time PCR, and data analysis
were performed as previously described (Della Torre et al., 2011). The primers
used are listed in the Supplemental Experimental Procedures.
Cell Cultures and Transfections
See Supplemental Experimental Procedures.
Co-regulator Recruitment by FRET Assays
See Supplemental Experimental Procedures.
ChIP-qPCR Experiments
ChIP-qPCR experiments were conducted as previously described (Uhlen-
haut et al., 2013): formaldehyde-fixed mouse liver chromatin was pro-
cessed for ChIP using the following antibodies: ERa (sc-542, Santa Cruz
Biotechnology) and LXRa (pp-pp70412-00, R&D Systems); and SYBR
Green qPCR was performed on a ViiA 7 instrument (Applied Biosystems).Cell Reports 15, 360–371, April 12, 2016 369
The primer sequences are listed in the Supplemental Experimental
Procedures.
Statistical Analyses
Unless otherwise stated, statistical significance was assessed by one-way or
two-way ANOVA using Bonferroni’s multiple comparison post hoc tests that
were performed with GraphPad Prism 5 (GraphPad Software). *p < 0.05,
**p < 0.01 and ***p < 0.001 versus SYN at P; Op < 0.05, OOp < 0.01 and
OOOp < 0.001 versus LERKO at P; #p < 0.05, ##p < 0.01 and ###p < 0.001
versus SYN.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.03.019.
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